Oncolytics Biotech (TSE:ONC) Stock Price Crosses Below 200-Day Moving Average – Here’s What Happened

Shares of Oncolytics Biotech Inc. (TSE:ONC) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$14.90 and traded as low as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares traded.

Oncolytics Biotech Price Performance

The company has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The company has a current ratio of 2.88, a quick ratio of 8.86 and a debt-to-equity ratio of 14.58. The company has a fifty day moving average price of C$14.90 and a two-hundred day moving average price of C$14.90.

Insider Transactions at Oncolytics Biotech

In other Oncolytics Biotech news, Director Deborah Brown purchased 25,000 shares of the stock in a transaction on Thursday, February 12th. The shares were purchased at an average price of C$1.17 per share, with a total value of C$29,250.00. Following the acquisition, the director directly owned 109,851 shares of the company’s stock, valued at C$128,525.67. This represents a 29.46% increase in their position. Also, Director Wayne Pisano acquired 30,000 shares of the company’s stock in a transaction dated Thursday, February 12th. The stock was acquired at an average price of C$1.16 per share, with a total value of C$34,800.00. Following the purchase, the director owned 288,306 shares in the company, valued at approximately C$334,434.96. This represents a 11.61% increase in their position. Over the last three months, insiders have purchased 289,232 shares of company stock worth $335,760. 3.82% of the stock is currently owned by company insiders.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.